Pharma & Biotech Events & Conferences
Refine Search
Pharmaceutical
Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) provided a statistically-significant overall survival benefit at 24 months (23% reduction of risk of death) compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). 2 October 2024
Biotechnology
US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of Amvuttra (vutrisiran), an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). 30 September 2024
Biotechnology
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Pharmaceutical
Israeli drugmaker Teva Pharmaceuticals has announced new findings from research that could shape treatment strategies in schizophrenia and tardive dyskinesia (TD). 23 September 2024
Pharmaceutical
Presentations at the European Society for Medical Oncology (ESMO) Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer cachexia, a life-threatening wasting condition in cancer patients. Belgo-American drug developer iTeos Therapeutics announced mixed data at ESMO on its anti-TIGIT belrestotug, under development with UK pharma major GSK. Also of note, Germany’s BioNTech presented mid-stage at ESMO for its BNT327 in lung cancer. In other significant developments, Organon announced it is acquiring Roivant Sciences subsidiary Dermavant for up to $1.2 billion, but only $175 million upfront. Denmark’s Novo Nordisk released Phase IIa results for its recently-acquired obesity candidate monlunabant. 22 September 2024
Pharmaceutical
Sanofi has announced encouraging results from its Phase III HERCULES trial of tolebrutinib in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS). 20 September 2024
Biotechnology
TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS). 19 September 2024
Biotechnology
US biotech major Regeneron has shown that the addition of its investigational LAG-3 inhibitor fianlimab to its PD-1 inhibitor Libtayo (cemiplimab) offers impressive results in advanced melanoma. 17 September 2024
Biotechnology
A cancer drug in-licensed by German biotech major BioNTech from China-based Biotheus could be a good one, if mid-stage results shared at the European Society for Medical Oncology (ESMO) are anything to go by. 17 September 2024
Biotechnology
Eisai and Merck & Co have announced positive data for their combination therapy of Lenvima (lenvatinib) and Keytruda (pembrolizumab) in liver cancer. 17 September 2024
Biotechnology
Swiss pharma giant has shared a well-timed updated analysis from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2024 16 September 2024
Pharmaceutical
German pharma major Bayer today released results from the Phase III ARANOTE trial at the European Society for Medical Oncology (ESMO) taking place in Spain. 16 September 2024
Pharmaceutical
Swiss pharma giant has shared a well-timed updated analysis from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2024. 16 September 2024
Biotechnology
As ever, US pharma giant Merck & Co has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) at this year’s meeting of the European Society for Medical Oncology (ESMO). 16 September 2024
Biotechnology
Positive results from the NIAGARA Phase III trial showed that UK pharma major AstraZeneca’s (LSE: AZN) Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically-significant and clinically-meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). 16 September 2024
Biotechnology
The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15, said US pharma giant Pfizer. 16 September 2024
Pharmaceutical
Pfizer released longer-term follow-up results from the Phase II single-arm PHAROS clinical trial evaluating the efficacy and safety of Braftovi (encorafenib) in combination with Mektovi (binimetinib) for patients with BRAF V600E - mutant metastatic non-small cell lung cancer (NSCLC). 16 September 2024
Biotechnology
Incyte has announced that its Phase III POD1UM-303/InterAACT2 trial met its primary endpoint of progression-free survival (PFS). 16 September 2024
Biotechnology
US pharma giant Merck & Co announced positive overall survival (OS) results from the final analysis of the Phase III KEYNOTE-811 trial. 14 September 2024
Pharmaceutical
In Alzheimer's, most of the focus has been on the newly-emerging class of intravenous biologics for early-stage disease, and the potential for subcutaneous versions to widen access and improve the patient experience. 17 July 2023
Biotechnology
Alnylam Pharmaceuticals is hoping a long-acting injection targeting amyloid-beta could be the next step in the emerging field of early Alzheimer’s treatment. 17 July 2023
Pharmaceutical
On Sunday, Singapore-headquartered TauRx Pharmaceuticals presented new data from the Phase III LUCIDITY trial that measured the impact of the company’s drug candidate, hydromethylthionine mesylate (HMTM), on neurofilament light chain (NfL), an established biomarker for brain neurodegeneration 17 July 2023
Biotechnology
The recent full approval of Leqembi (lecanemab-irmb) has upped the stakes for what promises to be a particularly intriguing congress of the Alzheimer’s Association next week. 12 July 2023
Biotechnology
Spanish skincare specialist Almirall has announced positive results from a real-world study of Ilumetri (tildrakizumab) at the 25th World Congress of Dermatology. 7 July 2023
Biotechnology
Eisai has broken new ground in the development of Alzheimer's treatments, gaining the first approval for decades. In the runup to AAIC 2023, we discuss progress with the deputy chief clinical officer of the firm's American business. 6 July 2023
Biotechnology
German family-owned pharma major Boehringer Ingelheim today presented new late-breaking data from the EFFISAYIL trial showing that patients receiving the highest dose of spesolimab experienced significantly reduced generalized pustular psoriasis (GPP) flares by 84% over 48 weeks compared to placebo (hazard ratio 0.157; 95% confidence interval 0.05–0.54; p=0.0005). 4 July 2023
Biotechnology
News coming out of Cure SMA meeting on new 36-month extension data from US biotech Scholar Rock’s Phase II TOPAZ clinical trial reinforces long-term substantial and sustained improvement of motor function in patients with non-ambulatory spinal muscular atrophy (SMA) treated with apitegromab. 3 July 2023
Biotechnology
Israel’s largest drugmaker Teva Pharmaceutical Industries has announced further positive data from the pan-European PEARL study investigating the impact of Ajovy (fremanezumab) on the prevention of migraine in a real-world setting, due to be completed in 2024. 1 July 2023
Pharmaceutical
BioXcel has presented positive top-line results for TRANQUILITY II, a Phase III trial of BXCL501, its orally dissolving film formulation of dexmedetomidine under investigation for the acute treatment of Alzheimer’s disease-related agitation. 29 June 2023
Pharmaceutical
US clinical stage biotech RenovoRx saw its shares leap 30% to $2.90 in pre-market activity, after it released positive interim Phase III data showing an 8-month improvement in progression-free survival (PFS) for patients on RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer. 29 June 2023
Pharmaceutical
Traders have taken a downbeat view of Cognition Therapeutics’ prospects, with top-line results from a Phase II trial shaking confidence in the firm’s Alzheimer’s research. 29 June 2023
Pharmaceutical
The race to provide obesity treatments on Monday seems have raised the bar, as an experimental weight-loss compound from US pharma major Eli Lilly yielded the strongest results of any treatment seen so far. 27 June 2023
Biotechnology
Japanese pharma major Takeda has presented positive interim results from a global Phase III trial of TAK-755. 26 June 2023
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim seems to be challenging front runners in the obesity treatment therapy sector with its candidate survodutide, but tolerability issues could be a problem. 26 June 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk on Sunday released new data from the Phase IIIa ONWARDS 1 and 3 trials evaluating investigative once-weekly basal insulin icodec at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA). 26 June 2023
Pharmaceutical
In the USA, people with the most severe form of hepatitis have reason to cheer as Gilead Sciences announces new positive data at the annual congress of the European Association for the Study of the Liver (EASL). 23 June 2023
Pharmaceutical
AstraZeneca’s real-world evidence (RWE) ZORA study shows the negative consequences of reducing or discontinuing life-saving renin-angiotensin-aldosterone system inhibitor (RAASi) medication in patients experiencing hyperkalemia (HK). 19 June 2023
Biotechnology
Adding to the bank of positive clinical evidence for its already-marketed drug, Danish CNS specialist Lundbeck today released new data confirming long-term benefit of treatment with Vyepti (eptinezumab) in migraine prevention. 16 June 2023
Biotechnology
Privately-held Californian firm Alladapt Immunotherapeutics has announced top-line results from the Phase I/II Harmony study of its multi-targeted allergy treatment ADP101. 14 June 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze